iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)
Glaukos Corporation · Decision date Jun 21, 2018
What did the FDA approve?
FDA approved the iStent inject Trabecular Micro-Bypass System (Model G2-M-IS) on June 21, 2018, under PMA number P170043. The approval statement describes the device as indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.
The applicant is Glaukos Corporation, and the device is classified under product code OGO as an intraocular pressure lowering implant in the ophthalmic specialty. The source statement reports the device's stated purpose but does not itself provide independent evidence of safety or clinical effectiveness. No supplement type or supplement reason is recorded, so the entry appears to reflect the original PMA approval rather than a change to an existing approval.
FDA approval order statement
Approval for the iStent inject Trabecular Micro-Bypass System (Model G2-M-IS). This device is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Jun 21, 2018
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170043
- Regulatory pathway
- Premarket approval application
- Applicant
- Glaukos Corporation
- Product code
- OGO
- Decision code
- APPR
- Decision date
- Jun 21, 2018
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intraocular pressure lowering implant.
- Applicant
- Glaukos Corporation
- Product code
- OGO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P170043 received
Application receipt date recorded by FDA.
P170043 · FDA decision
APPR
P170043/S023 · Related supplement
Glaukos iStent inject W Trabecular Micro-Bypass System, Glaukos iStent inject W Trabecular Micro-Bypass System with
Timeline entries are records held by MedtechLedger for P170043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Glaukos Corporation | PMA supplement | Oct 1, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Glaukos Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 229 Avenida Fabricante, San Clemente, CA, 92672
Sources and methodology
- Original FDA record: P170043
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records